Effectiveness of neoadjuvant chemotherapy for patients with resectable pancreatic cancer

MOTOI Fuyuhiko, MIZUMA Masamichi, UNNO Michiaki

doi:10.2958/suizo.36.3

<p>Although upfront surgery has been the standard strategy for patients with resectable pancreatic cancer, the Prep-02/JSAP05 study has recently demonstrated that neoadjuvant chemotherapy significantly improves survival outcome of patients with planned pancreatic cancer resection. We conducted a single-center, retrospective analysis to confirm the effectiveness of neoadjuvant chemotherapy for 294 patients with pancreatic cancer who had planned resection. Neoadjuvant chemotherapy was administered generally with a regimen of 2 cycles of gemcitabine plus S1. The resection rate of the group treated with neoadjuvant chemotherapy, used in patients with more advanced disease than those treated with upfront surgery, was significantly higher than those treated with upfront surgery. No significant differences in perioperative findings between the groups was observed including operative time, blood loss, or initiation of post-operative adjuvant therapy. The median overall survival in the neoadjuvant chemotherapy group was 42.2 months, significantly longer than that of the upfront surgery group. Significant improvement of overall survival in patients who received neoadjuvant chemotherapy was also observed in the subset of resectable patients. This study confirms the superiority of neoadjuvant chemotherapy over upfront surgery as reported in the Prep-02/JSAP05 study. This strategy may be widely useful as a standard best practice for patients with resectable pancreatic cancer hereafter.</p>

Effectiveness of neoadjuvant chemotherapy for patients with resectable pancreatic cancer

Bibliographic Information

Search this article

Description

Journal

References(24)*help

Keywords

Details 詳細情報について

Export

Report a problem